Our proprietary technology enables the eye to generate its own therapeutic proteins.
Our novel non-viral gene therapy platform turns the eye into a production site for sustained delivery of therapeutic proteins by introducing proprietary DNA plasmids encoding therapeutic proteins directly into the ciliary muscle via our patented Electrotransfection System. Our unique approach offers the possibility of a wide range of targeted, long-lasting treatments that are safe, convenient, and effective.
All drug delivery approaches for retinal diseases have significant limitations:
- Intravitreal injections require frequent readministrations leading to fluctuating peak and trough drug levels.
- Viral vector gene therapy may require invasive subretinal surgery with a high risk of damage to the retina or other safety issues associated with viral vectors.
- Ocular implants involve introducing a foreign body into the eye and can result in corticosteroid-related ocular side effects.
- Systemic treatments have poor ocular bioavailability, require constant lab monitoring resulting in poor compliance, and can have significant side effects.